Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY study of inebilizumab in autoimmune hepatitis
2025-522393-37-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of inebilizumab in autoimmune hepatitis (AIH) (3 arms), sponsored by Amgen. Primary endpoints: Safety during first 26 weeks and Histologic response with steroid control at CCI. Planned start Oct 2026; status: authorised.
02
Drugs
inebilizumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on 2025-522393-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522393-37-00.